期刊文献+

c-Kit在进展期胃癌组织中的表达及其与预后的关系

Relationship between c-Kit expression and prognosis of advanced gastric cancer
下载PDF
导出
摘要 目的研究进展期胃癌组织c-Kit表达及与相关指标和预后的关系,以探讨c-Kit能否作为胃癌分子靶向药物治疗靶点。方法采用免疫组化法研究了69例进展期胃癌组织标本的c-Kit表达及与MDR1和SSTR2的相关性,并对患者进行总生存期随访。结果进展期胃癌组织c-Kit阳性表达率为24.6%。c-Kit表达与患者性别、年龄、分期、分化及脉管和神经侵犯均无相关性。肿瘤组织c-Kit表达与MDR1(P=0.049)和SSTR2(P=0.013)表达有相关性。c-Kit表达阴性患者中位总生存期为13.8个月(95%CI 11.8~15.8个月),c-Kit表达阳性患者中位总生存期为12.5个月(95%CI9.58~15.42个月,P=0.049),两者差异具有统计学意义。ⅢA期病例c-Kit表达阴性患者中位总生存期为26.1个月(95%CI15.36~36.84个月),c-Kit表达阳性患者中位总生存期仅为12.5个月(95%CI7.51~17.49个月,P=0.04)。结论 c-Kit可能是胃癌靶向酪氨酸激酶抑制剂使用靶点,但其相关机制有待体内外研究证实。 Objective To explore the relationship between c-Kit expression and prognosis of advanced gastric cancer.Methods c-Kit expression was detected in tissue samples from 69cases of advanced gastric cancer by using immunochemistry,and its relationship with DMR1and SSTR2was analyzed.Survival data of all patients were analyzed by follow-up.Results The positive rate of c-Kit expression was 24.6%.c-Kit expression was not related to gender,age,stage,histological differentiation,and nerves and vessels involvement,but was related to MDR1(P= 0.049)and SSTR2(P=0.013)expression.The median overall survival of c-Kit negative patients was 13.8months(95%CI:11.8-15.8months),while the median overall servival was 12.5months(95%CI:9.58-15.42months) in c-Kit positive patients,and the difference between the two groups was significant(P=0.049).The median overall servival of c-Kit negative and positive patients at stageⅢA were 26.1months(95%CI:15.36-36.84months)and 12.5months(95% CI:7.51-17.49months),and the difference was significant(P=0.04).Conclusion c-Kit expression might be related to survival of patients with advanced gastric cancer and could be a potential therapeutic target,which should be confirmed by further investigation.
出处 《检验医学与临床》 CAS 2013年第19期2497-2498,2502,共3页 Laboratory Medicine and Clinic
基金 国家自然科学基金资助项目(81172094 81000980 81101751)
关键词 C-KIT 胃癌 预后 c-Kit gastric cancer prognosis
  • 相关文献

参考文献9

  • 1Went PT,Dirnhofer S, Bundi M, et al. Prevalence of KIT expression in human tumors [J]. J Clin Oncol, 2004,22 (22) :4514-4522.
  • 2Singer CF, Hudelist G, Lamm W, et al. Expression of tyrosine kinases in human malignancies as potential tar- gets for kinase-specifie inhibitors [J]. Endoer Relat Canc- er, 2004,11 (4) : 861-869.
  • 3Ashman LK. The biology of stem cell factor and its recep- tor C-kit[J]. Int J Biochem Cell Biol, 1999,31 (10) : 1037- 1051.
  • 4Rivera RS, Nagatsuka H, Gunduz M, et al. C-kit protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma[J]. Virchows Arch, 2008, 452(1) :27-32.
  • 5Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advaneed gastrointesti- nal stromal tumors, [J]. N Engl J Med, 2002,34? (?): 472-480.
  • 6Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumors with high-dose imatinib : randomised trial [J]. Lancet, 2004 ; 364 ( 9440 ) : 1127-1134.
  • 7Carvajal RD, Antonescu CR,Wolchok JD, et al. KIT as a therapeutic target in metastatic melanoma [J]. JAMA, 2011,305(22) :2327-2334.
  • 8Guo J, Si L, Kong Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic mela- noma harboring c-Kit mutation or amplification[J]. J Clin Oncol,2011,29 (21) :2904-2909.
  • 9Gupta PB, Onder TT,Jiang G, et al. Identification of se- lective inhibitors of Cancer stem cells by high-throughput screening[J]. Cell, 2009,138(4) : 645-659.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部